Drug intelligence / Profile preview

GB-5001D

Development stage: Phase 1
Lead developer: G2GBio
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intramuscular, Subcutaneous

Overview

GB-5001D is a sustained-release, long-acting injectable formulation of donepezil, an acetylcholinesterase inhibitor, being developed by G2GBio for the treatment of Alzheimer's disease. Utilizing G2GBio's proprietary InnoLAMP® technology, the drug encapsulates donepezil within biodegradable PLGA (poly(lactic-co-glycolic acid)) microspheres. This formulation is designed for once-monthly intramuscular or subcutaneous administration, aiming to improve patient compliance and maintain stable plasma concentrations compared to daily oral donepezil (Aricept). It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetic profile in healthy volunteers.

Other names: donepezil sustained-release injectiondonepezil depot injection

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on GB-5001D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-5001D.